Guardian Pharmacy Services Future Growth

Future criteria checks 3/6

Guardian Pharmacy Services is forecast to grow earnings and revenue by 106% and 6.6% per annum respectively while EPS is expected to grow by 105.3% per annum.

Key information

106.0%

Earnings growth rate

105.3%

EPS growth rate

Consumer Retailing earnings growth	10.4%
Revenue growth rate	6.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	15 Nov 2024

Recent future growth updates

Recent updates

Guardian Pharmacy Services: Questions After A Successful IPO

Oct 02

Earnings and Revenue Growth Forecasts

NYSE:GRDN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,358	57	58	78	3
12/31/2025	1,326	48	52	72	3
12/31/2024	1,210	-73	43	56	3
9/30/2024	1,171	-98	36	50	N/A
6/30/2024	1,119	24	53	67	N/A
3/31/2024	1,085	29	58	72	N/A
12/31/2023	1,046	24	56	71	N/A
9/30/2023	1,002	12	50	66	N/A
6/30/2023	976	23	45	62	N/A
3/31/2023	947	19	38	55	N/A
12/31/2022	909	35	32	49	N/A
9/30/2022	882	19	39	53	N/A
3/31/2022	822	34	49	60	N/A
12/31/2021	792	16	49	58	N/A
9/30/2021	771	31	48	57	N/A
3/31/2021	732	21	46	54	N/A
12/31/2020	736	20	44	53	N/A
9/30/2020	730	16	44	55	N/A
12/31/2019	698	22	42	56	N/A
9/30/2019	677	17	37	50	N/A
12/31/2018	600	15	34	44	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GRDN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: GRDN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GRDN is expected to become profitable in the next 3 years.

Revenue vs Market: GRDN's revenue (6.6% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: GRDN's revenue (6.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GRDN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 06:59
End of Day Share Price	2024/12/26 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guardian Pharmacy Services, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kam Wai Kwok	CGS International
John Ransom	Raymond James & Associates
Scott Fidel	Stephens, Inc.